Premium
Cardiac troponin I in canine patients with lymphoma and osteosarcoma receiving doxorubicin: comparison with clinical heart disease in a retrospective analysis
Author(s) -
Selting K. A.,
Lana S. E.,
Ogilvie G. K.,
Olmstead A.,
Mykles D. L.,
Bright J.,
Richardson K. L.,
Walton J. A.,
Monnet E.,
Fettman M. J.
Publication year - 2004
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5810.2004.00051.x
Subject(s) - medicine , troponin i , cardiotoxicity , doxorubicin , chemotherapy , cardiomyopathy , troponin , heart failure , cardiology , lymphoma , anthracycline , cancer , retrospective cohort study , osteosarcoma , oncology , gastroenterology , pathology , breast cancer , myocardial infarction
The cumulative cardiotoxicity that occurs as a result of doxorubicin chemotherapy is irreversible and can affect both quality and quantity of life for the cancer patient. Cardiac troponin I (cTnI) is a sensitive and specific marker of cardiomyocyte death. The purpose of this retrospective study was to evaluate serum concentrations of cTnI in dogs with lymphoma or osteosarcoma given doxorubicin chemotherapy, and with known cardiac outcome, based on a minimum assessment by physical examination and thoracic radiography. Serum samples were also available for cTnI measurement from seven healthy dogs given intracoronary doxorubicin. Serial serum samples obtained before, during and after doxorubicin chemotherapy showed increased cTnI concentrations in some clinical patients following chemotherapy ( P = 0.0083 compared to baseline), but this did not correlate with clinical signs of cardiomyopathy. In dogs that subsequently developed cardiomyopathy however, serum cTnI concentrations were elevated before clinical signs became evident (confirmed with echocardiography).